Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: Comparison of efficacy in animal models with human clinical data

Arthritis and Rheumatism

Volumn 42, Issue 3, 1999, Pages 498-506

  Bendele, Alison ^a   McAbee, Tracy ^a   Sennello, Gina ^a   Frazier, Jan ^a   Chlipala, Elizabeth ^a   McCabe, Dorothy ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; BONE INJURY; BONE RADIOGRAPHY; CELL PROLIFERATION; COLLAGEN METABOLISM; COMPETITIVE INHIBITION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANKLE JOINT; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; COLLAGEN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; RATS; RATS, INBRED LEW; RECEPTORS, INTERLEUKIN-1; SIALOGLYCOPROTEINS;

EID: 0033016267     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199904)42:3<498::AID-ANR15>3.0.CO;2-A     Document Type: Article

References (19)

1. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor a in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
2. Van de Loo FAJ, Joosten LAB, van Lent PLEM, Arutz OJ, van der Berg WB. Role of interleukin-1, tumor necrosis factor a and interleukin-6 in cartilage proteoglycan metabolism and destruction: effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum;1995;38:164-72.
3. Eastgate JA, Wood NC, diGiovine FS, Symons JA, Grinlinton JA, Duff GW. Correlation of plasma interleukin-1 levels with disease activity in rheumatoid arthritis. Lancet 1988;24:706-9.
4. Khale P, Saal JG, Schaudt K. Determination of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of synovial tissue. Ann Rheum Dis 1992;51:731-4.
5. Eisenberg SP, Evans RJ, Arend WP. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990;343:341-5.
6. Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M, and The IL-1Ra Arthritis Study Group. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1092-101.
7. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-2204.
8. Schwab JH, Anderle SK, Brown RR, Dalldorf FG, Thompson RC. Pro- and anti-inflammatory roles of interleukin-1 in recurrence of bacterial cell wall-induced arthritis in rats. Infect Immun 1991;59: 4436-42.
9. Pearson CM. Development of arthritis, periarthritis and periostitis in rats given adjuvants. Proc Soc Exp Biol Med 1956;91:95-100.
10. Carlson RP, Datko LJ, O'Neil-Davis L, Blazek EM, Delustro F, Beideman R, et al. Comparison of inflammatory changes in established type II collagen and adjuvant induced arthritis using outbred Wistar rats. Int J Immunopharmacol 1985;7:811-26.
11. Benslay DN, Bendele AM. Development of a rapid screen for detecting and differentiating immunomodulatory vs. antiinflammatory compounds in rats. Agents Actions 1991;34:254-6.
12. Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen: an experimental model of arthritis. J Exp Med 1977;146: 857-68.
13. Terato K, Hashida R, Miyamoto K, Morimoto T, Kata Y, Kobayashi S, et al. Histological, immunological, and biochemical studies on type II collagen arthritis in rats. Biomed Res 1982;3:495-523.
14. Kimble RB, Vannice JL, Bloedow DC, Thompson RC, Hopfer W, Kung VT, et al. Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. J Clin Invest 1994;93:1959-67.
15. Makarov SS, Olsen JC, Johnston WN, Anderle SK, Brown RR, Baldwin AS, et al. Suppression of experimental arthritis by gene transfer of interleukin-1 receptor antagonist cDNA. Proc Natl Acad Sci USA 1996;93:402-6.
16. Van de Loo FAJ, Arntz OJ, Otterness IG, van den Berg WB. Protection against cartilage proteoglycan synthesis inhibition by antiinterleukin 1 antibodies in experimental arthritis. J Rheumatol 1992;19:348-56.
17. Van Lent PL, van de Loo FAJ, Holthuysen AEM, Liduine AM, van den Bersselaar, Vermeer H, et al. Major role for interleukin 1 but not for tumor necrosis factor in early cartilage damage in immune complex arthritis in mice. J Rheumatol 1995;22: 2250-7.
18. Wooley PH, Whalen JD, Chapman DL, Berger AE, Richard KA, Aspar DG, et al. The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum 1993;36:1305-14.
19. Joosten LAB, Helsen MMA, van de Loo FAJ, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-lα/β, and IL-IRa. Arthritis Rheum 1996;39:797-809.